Novartis hit on Gleevec in U.S. tells the tale for India's Sun Pharma

Novartis HQ

Novartis ($NVS) held about half its market share as India's Sun Pharmaceuticals launched a generic version of blood cancer drug Gleevec/Glivec (imatinib) in the U.S. at the start of February--but that figure is expected to collapse by the third quarter as the 180-day market exclusivity ends and a swarm of new offers appear.

David Epstein, head of pharma for the Swiss-based firm, discussed the loss of exclusivity in the world's top market at length on a recent earnings call, setting up Mumbai-based Kotak Institutional Equities analysts Chirag Talati and Kumar Gaurav to work backward and crunch a few numbers in relation to Sun's launch.

Epstein noted that the overall pharma division sales were up 1% in the first quarter and would have gained 4% without the loss of exclusivity for the oncology therapy in the U.S.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

The analysts noted that Novartis' first-quarter results suggest 35% to 40% price erosion for Gleevec in the U.S., with Novartis retaining over 50% market share so far, according to a note to clients.

"We believe the key sensitivity for Gleevec is the competition it will face after the 180-day exclusivity," the analysts said, adding that by the second half of 2018, "We expect pricing to collapse by 80-90% and face further erosion over time as the market eventually will settle at eight-to-10 players."

Epstein too sees a price collapse--but a little bit quicker.

"There will be multiple generics entering in, if I recall correctly, in Q3 of this year," he said on the call. "It's hard to know exactly how many, but would not be surprising if there were four, 5 or 6 of them. If history is any guide, prices will more or less collapse at that point in time, and you would expect then our volume to become fairly small."

Kotak, placing a sell recommendation on Sun citing the upcoming Gleevec competition and ongoing restructuring, said among the players ready to come in on day 181 are Toronto-based Apotex, using an API from Hyderabad-based Natco Pharma, and Israel's Teva, using an API from Croatia-based unit Pliva.

- here's the Novartis release

Suggested Articles

It’s a familiar scene in the race onto China’s national reimbursement list: Drugmakers cut prices by an average 60.7% to win coverage.

After a longer follow-up of 25 months, Alunbrig cut the risk of disease progression by 51% compared with Xalkori in ALK inhibitor-naïve NSCLC.

Novartis pivots Shanghai R&D from discovery to development. BeiGene nabs FDA nod for BTK inhibitor Brukinsa. FDA clears Shionogi's antibiotic Fetroja.